Current evidence for monitoring platelet reactivity in acute coronary syndrome: A plea for individualized antiplatelet treatment

D. Aradi, Dirk Sibbing, Laurent Bonello

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Although clopidogrel is more effective in preventing thrombotic complications than aspirin alone in a broad spectrum of patients with ischemic heart disease, many of its limitations were recently brought to light including a delayed onset of action and highly unpredictable P2Y12-receptor inhibition. New-generation ADP-receptor antagonists, such as prasugrel and ticagrelor, were designed and developed to overcome these limitations, providing a more rapid, more reliable and more potent P2Y12-receptor inhibition. These pharmacodynamic benefits of new-generation antiplatelet agents were translated into significant clinical advantage among patients with acute coronary syndrome (ACS), especially in preventing stent thrombosis. However, the downsides of the unselected use of novel P2Y12-receptor antagonists include higher risk of bleeding and increased costs. Platelet reactivity testing might become a useful tool to help balance between bleeding and thrombosis with P2Y12-receptor antagonists; however, its role in clinical practice for patients undergoing percutaneous coronary intervention (PCI) remains uncertain. The aim of this viewpoint article is to summarize the currently available evidence supporting a role of platelet function testing in patients with ACS after PCI.

Original languageEnglish
Pages (from-to)1794-1797
Number of pages4
JournalInternational Journal of Cardiology
Volume167
Issue number5
DOIs
Publication statusPublished - Sep 1 2013

Fingerprint

Purinergic P2Y Receptor Antagonists
Acute Coronary Syndrome
Blood Platelets
clopidogrel
Percutaneous Coronary Intervention
Thrombosis
Hemorrhage
Platelet Aggregation Inhibitors
Therapeutics
Aspirin
Stents
Myocardial Ischemia
Costs and Cost Analysis

Keywords

  • Acute coronary syndrome
  • Clopidogrel
  • Individualized antiplatelet treatment
  • Platelet function testing
  • Prasugrel
  • Ticagrelor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Current evidence for monitoring platelet reactivity in acute coronary syndrome : A plea for individualized antiplatelet treatment. / Aradi, D.; Sibbing, Dirk; Bonello, Laurent.

In: International Journal of Cardiology, Vol. 167, No. 5, 01.09.2013, p. 1794-1797.

Research output: Contribution to journalArticle

@article{5f21e8bcb74e47118430b599d8bba793,
title = "Current evidence for monitoring platelet reactivity in acute coronary syndrome: A plea for individualized antiplatelet treatment",
abstract = "Although clopidogrel is more effective in preventing thrombotic complications than aspirin alone in a broad spectrum of patients with ischemic heart disease, many of its limitations were recently brought to light including a delayed onset of action and highly unpredictable P2Y12-receptor inhibition. New-generation ADP-receptor antagonists, such as prasugrel and ticagrelor, were designed and developed to overcome these limitations, providing a more rapid, more reliable and more potent P2Y12-receptor inhibition. These pharmacodynamic benefits of new-generation antiplatelet agents were translated into significant clinical advantage among patients with acute coronary syndrome (ACS), especially in preventing stent thrombosis. However, the downsides of the unselected use of novel P2Y12-receptor antagonists include higher risk of bleeding and increased costs. Platelet reactivity testing might become a useful tool to help balance between bleeding and thrombosis with P2Y12-receptor antagonists; however, its role in clinical practice for patients undergoing percutaneous coronary intervention (PCI) remains uncertain. The aim of this viewpoint article is to summarize the currently available evidence supporting a role of platelet function testing in patients with ACS after PCI.",
keywords = "Acute coronary syndrome, Clopidogrel, Individualized antiplatelet treatment, Platelet function testing, Prasugrel, Ticagrelor",
author = "D. Aradi and Dirk Sibbing and Laurent Bonello",
year = "2013",
month = "9",
day = "1",
doi = "10.1016/j.ijcard.2012.12.026",
language = "English",
volume = "167",
pages = "1794--1797",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "5",

}

TY - JOUR

T1 - Current evidence for monitoring platelet reactivity in acute coronary syndrome

T2 - A plea for individualized antiplatelet treatment

AU - Aradi, D.

AU - Sibbing, Dirk

AU - Bonello, Laurent

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Although clopidogrel is more effective in preventing thrombotic complications than aspirin alone in a broad spectrum of patients with ischemic heart disease, many of its limitations were recently brought to light including a delayed onset of action and highly unpredictable P2Y12-receptor inhibition. New-generation ADP-receptor antagonists, such as prasugrel and ticagrelor, were designed and developed to overcome these limitations, providing a more rapid, more reliable and more potent P2Y12-receptor inhibition. These pharmacodynamic benefits of new-generation antiplatelet agents were translated into significant clinical advantage among patients with acute coronary syndrome (ACS), especially in preventing stent thrombosis. However, the downsides of the unselected use of novel P2Y12-receptor antagonists include higher risk of bleeding and increased costs. Platelet reactivity testing might become a useful tool to help balance between bleeding and thrombosis with P2Y12-receptor antagonists; however, its role in clinical practice for patients undergoing percutaneous coronary intervention (PCI) remains uncertain. The aim of this viewpoint article is to summarize the currently available evidence supporting a role of platelet function testing in patients with ACS after PCI.

AB - Although clopidogrel is more effective in preventing thrombotic complications than aspirin alone in a broad spectrum of patients with ischemic heart disease, many of its limitations were recently brought to light including a delayed onset of action and highly unpredictable P2Y12-receptor inhibition. New-generation ADP-receptor antagonists, such as prasugrel and ticagrelor, were designed and developed to overcome these limitations, providing a more rapid, more reliable and more potent P2Y12-receptor inhibition. These pharmacodynamic benefits of new-generation antiplatelet agents were translated into significant clinical advantage among patients with acute coronary syndrome (ACS), especially in preventing stent thrombosis. However, the downsides of the unselected use of novel P2Y12-receptor antagonists include higher risk of bleeding and increased costs. Platelet reactivity testing might become a useful tool to help balance between bleeding and thrombosis with P2Y12-receptor antagonists; however, its role in clinical practice for patients undergoing percutaneous coronary intervention (PCI) remains uncertain. The aim of this viewpoint article is to summarize the currently available evidence supporting a role of platelet function testing in patients with ACS after PCI.

KW - Acute coronary syndrome

KW - Clopidogrel

KW - Individualized antiplatelet treatment

KW - Platelet function testing

KW - Prasugrel

KW - Ticagrelor

UR - http://www.scopus.com/inward/record.url?scp=84883294505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883294505&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2012.12.026

DO - 10.1016/j.ijcard.2012.12.026

M3 - Article

C2 - 23290951

AN - SCOPUS:84883294505

VL - 167

SP - 1794

EP - 1797

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 5

ER -